Eli Lilly’s Oral GLP-1 Pill Foundayo Gains FDA Approval on April 1
Eli Lilly’s oral GLP-1 pill Foundayo gained FDA approval on April 1 and will reach pharmacies nationwide soon, joining Novo Nordisk’s Wegovy. The shift to a pill format and recent government price-cut initiatives could drive significant uptake and boost Eli Lilly’s weight-loss drug revenues.
1. Foundayo FDA Approval and Market Introduction
On April 1, Eli Lilly’s oral GLP-1 pill Foundayo received FDA approval and is slated to reach pharmacies nationwide in early Q2, offering a convenient alternative to injectable therapies.
2. Demand Drivers and Revenue Outlook
Government initiatives to reduce weight-loss drug prices and competition with Novo Nordisk’s Wegovy are expected to amplify GLP-1 adoption, with analysts forecasting a significant revenue boost for Eli Lilly’s weight-loss franchise.
Related News
CAAP
April Traffic Up 2.6% to 7.075M, Cargo Volume Rises 1.3%
CAAP•
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
GOOG
Google, Blackstone Launch $5B AI Cloud JV with 500MW Capacity by 2027
GOOG•
NVDA
Nvidia Posts 85% Revenue Surge to $81.6B, Forecasts $91B Next Quarter
NVDA•
GS
Goldman Sachs to Lead $1.75 Trillion SpaceX IPO With $1.45B Bitcoin Disclosure
GS•
Sources
F